-
Healthcare
-

Radical Diagnostic Shake-Up: 'Sponge' Rollout to Bypass Acute Endoscopy Backlogs

By
Distilled post Editorial Team

In a consulting room behind a pharmacy counter in Nottingham or Mansfield, a patient swallows a small capsule attached to a thread. It dissolves in the stomach and a compressed sponge expands over about seven minutes. The pharmacist withdraws it, collecting cells from the lining of the oesophagus as it passes upwards. The appointment is brief, but the implications for the NHS are substantial. A task traditionally carried out in a hospital endoscopy suite has moved into the community, the sample goes to a laboratory and any abnormal result may return the patient to a gastroenterology service already struggling with demand.

That shift moved closer to national policy on 16 November, when NICE published its first draft guidance under the National HealthTech Access Programme (NHAP). It recommends Cytosponge and EndoSign capsule sponge tests for people with persistent reflux and several risk factors for oesophageal cancer who do not require an urgent suspected cancer referral. The draft also proposes them as an alternative surveillance route for selected people already diagnosed with Barrett's oesophagus. Consultation runs until 7 December, with final guidance expected in February 2027. This is not screening for everyone who takes antacids, and any national rollout is unlikely before 2027.

The attraction is clear. Evidence summarised alongside the draft records that 1,654 participants successfully swallowed the sponge. Of these, 231 received positive results, 221 proceeded to endoscopy, where 131 were diagnosed with Barrett's oesophagus or cancer. Around one in seven people tested therefore needed the hospital procedure, and a substantial proportion of those referrals produced a diagnosis. Used carefully, the test could spare many patients an invasive appointment and direct endoscopy capacity towards those more likely to need it.

NICE has recognised the pressure behind that proposition. Some people with Barrett's oesophagus receive surveillance less frequently than guidance recommends because demand for endoscopy is so high. The committee compared the sponge pathway with conventional endoscopy, which requires two nurses, an endoscopist and a hospital setting. The potential saving in staff time is significant. But a diagnostic filter is only as useful as the service that deals with the patients it identifies.

Early East Midlands pilot figures suggest planners should not assume the trial referral rate will hold in routine practice. By early August, 79 patients had been tested and 25 referred for endoscopy, roughly one in three. The sample is small and the pilot remains a research exercise awaiting evaluation, so it cannot provide a reliable forecast. It should, however, prompt integrated care boards to model more than one scenario. A service planned around a rate of one in seven could come under strain if local experience resembles the pilot. If positive results enter the existing surveillance queue, the new community front door may lead to the same congested corridor.

Laboratory capacity is another vulnerability. The sponge collects cells; diagnosis depends on a biomarker analysis carried out elsewhere. NICE's protocol states that Cytosponge samples are analysed by Cyted Health's laboratory. Cyted is also behind EndoSign, leaving both technologies reliant on the same analytical route. If national demand rises, that concentration will matter. Turnaround times could lengthen and undermine the speed promised at the pharmacy counter. Before volumes increase, the NHS needs contractual commitments on laboratory performance, contingency arrangements and resilience.

There is also a question about what the test can ultimately achieve. The sponge can detect Barrett's oesophagus, whether wider detection and surveillance reduce deaths from oesophageal adenocarcinoma is a separate matter. One response to the scoping consultation noted that positive randomised trial evidence of a mortality benefit from diagnosing and surveilling Barrett's remains absent. That does not invalidate the draft. NICE's committee considers the evidence on diagnostic accuracy and potential operational gains sufficient to support its recommendation. It does, however, make careful evaluation essential.

Evaluation must include people with negative results, not simply count tests and positive findings. A negative sponge test can offer reassurance, but it is no guarantee. Patients need to know what to do if symptoms persist or worsen, and pharmacists must explain the limits of the result. The pathway should make clear when further assessment is needed, rather than leaving patients to decide whether to seek help again.

The practical consequences will fall unevenly across the NHS. Integrated care boards and cancer alliances must turn the community diagnostic ambitions referenced in the Government's 10 Year Health Plan, and NICE's equality assessment, into funded services. Pharmacy pilots have relied on local arrangements. A national offer will need a sustainable contract covering the appointment, sample handling and follow-up. Endoscopy leads must decide whether released capacity will reduce surveillance backlogs or be taken up by additional patients referred after positive tests.

Suppliers will face scrutiny of laboratory turnaround, pricing and their ability to maintain service at higher volumes. Patients, meanwhile, are likely to encounter a postcode lottery for some time. The pharmacy pilots operate in twelve pharmacies across two regions, EndoSign is currently used at 18 English sites for detection and 30 for surveillance. This remains a developing service, not universal access.

The capsule may be swallowed in minutes, but the value of the result rests on a much larger system. NICE can recommend a technology; it cannot fund pharmacy appointments, staff endoscopy lists or guarantee a second laboratory if the first is overwhelmed. February's final guidance will determine whether the tests receive national backing. The harder judgement comes afterwards, when the NHS must show it can commission the service, process samples and act on what they reveal.